earnings
confidence high
sentiment positive
materiality 0.65
Vericel estimates FY2021 revenue growth 25-26%, adj. EBITDA ~$30M, cash ~$129M
Vericel Corp
2021-FY EPS reported
-$0.16
revenue$156,184,000
- Preliminary FY2021 revenue growth of 25%-26% (unaudited); total adjusted EBITDA ~$30M.
- Cash and investments as of Dec 31, 2021 ~$129M.
- Company presented at 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022.
- Financial results are preliminary and subject to change upon audit.